DelveInsight’s “Phenylketonuria Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products.
Some of the key takeaways of the Phenylketonuria Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Synlogic, Censa Pharmaceuticals, Homology Medicines, Biomarin Pharmaceuticals, etc., are developing therapies to treat Phenylketonuria.
-
Emerging therapies such as SYNB1618, CNSA-001, HMI-102, BMN 307, are expected to have a significant impact on the Phenylketonuria market in the coming years.
-
Rising mergers and acquisitions and collaboration activities among the major market participants are also estimated to drive the phenylketonuria treatment market.
Get an overview of pipeline landscape @ Phenylketonuria Clinical Trials Analysis
Phenylketonuria (PKU) is an inborn error of metabolism that is detectable during the first days of life via routine newborn screening. PKU is characterized by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), responsible for processing the amino acid phenylalanine.
Phenylketonuria Emerging Drugs
-
SYNB1618 by Synlogic
-
CNSA-001 by Censa Pharmaceuticals
-
HMI-102 by Homology Medicines
-
BMN 307 by Biomarin Pharmaceuticals
-
And others.
Scope of Phenylketonuria Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Synlogic, Censa Pharmaceuticals, Homology Medicines, Biomarin Pharmaceuticals, and others.
-
Pipeline Therapies: SYNB1618, CNSA-001, HMI-102, BMN 307, and others.
Table of Contents
|
1 |
Phenylketonuria Report Introduction |
|
2 |
Phenylketonuria Executive Summary |
|
3 |
Phenylketonuria Overview |
|
4 |
Phenylketonuria- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Phenylketonuria Pipeline Therapeutics |
|
6 |
Phenylketonuria Late Stage Products (Phase II/III) |
|
7 |
Phenylketonuria Mid Stage Products (Phase II) |
|
8 |
Phenylketonuria Early Stage Products (Phase I) |
|
9 |
Phenylketonuria Preclinical Stage Products |
|
10 |
Phenylketonuria Therapeutics Assessment |
|
11 |
Phenylketonuria Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Phenylketonuria Key Companies |
|
14 |
Phenylketonuria Key Products |
|
15 |
Phenylketonuria Unmet Needs |
|
16 |
Phenylketonuria Market Drivers and Barriers |
|
17 |
Phenylketonuria Future Perspectives and Conclusion |
|
18 |
Phenylketonuria Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
DelveInsight’s Phenylketonuria – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Phenylketonuria, historical and forecasted epidemiology as well as the Phenylketonuria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s ‘ Phenylketonuria- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Phenylketonuria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/